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scribed in this manner should be counseled about
the risks and clinical presentation of these and other
potential drug interactions.
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the authors reply: 
 
Drs. Grönefeld and Hohnloser
request information on antithrombotic treatment.
In our study protocol, anticoagulation was not stan-
dardized but was left to the local practice of each
center. Fifteen patients (7 percent) were treated with
warfarin, and 38 (18 percent) with aspirin. During
the follow-up period, no patient had a transient is-
chemic attack, stroke, or arterial embolism. How-
ever, we believe that the indications for antithrom-
botic therapy are not clearly defined in patients with
transient, symptomatic episodes of atrial fibrillation
that are treated with either the pill-in-the-pocket
approach or long-term oral prophylaxis; this point
deserves further investigation.
Drs. Konety and Olshansky underscore the lack
of a control group. In many studies carried out in
hospitalized patients, oral flecainide or propafe-
none has been shown to be superior to placebo in
rapidly terminating atrial fibrillation of recent onset.
In our opinion, further study to demonstrate this
superiority was not indicated. We agree with Drs.
Konety and Olshansky that the pill-in-the-pocket
approach should be used only in selected patients.
Current data show that flecainide and propafenone
are safe in patients without heart disease or with
only mild heart disease; thus, the exclusion criteria
we used should be strictly adopted in clinical prac-
tice. We enrolled highly symptomatic patients with
palpitations, who contacted the emergency room
for almost all the arrhythmic episodes, as shown in
Table 1 of our article. About one third of emergency
room visits were followed by hospitalization. Emer-
gency room visits and hospitalizations often repre-
sent the most important concern for patients with
recurrent atrial fibrillation. Not only did the pill-in-
the-pocket approach make the arrhythmic episodes
shorter, but it also dramatically reduced emergency
room visits and hospitalizations. Although these
patients were highly symptomatic with palpitations,
we cannot rule out asymptomatic arrhythmic epi-
sodes in some of them. However, this would not
represent a specific finding of the pill-in-the-pocket
approach, since asymptomatic episodes have been
observed during all antiarrhythmic treatments
(long-term oral prophylaxis, catheter ablation, and
pacemaker implantation).
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Dr. Wittkowsky raises the problem of drug inter-
actions. In particular, she refers to the interactions
of propafenone with digitalis or warfarin. In our
study, no patient was taking digitalis. The data on
the interactions between propafenone and warfarin
apply to long-term treatment with both drugs.
 
4
 
Moreover, we are not aware of any clinical study
reporting more hemorrhagic complications in pa-
tients receiving oral propafenone than in those re-
ceiving other antiarrhythmic agents.
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Vascular Events after Acute Infection or Vaccination
 
to the editor: 
 
In their article about cardiovascu-
lar events after acute infections (Dec. 16 issue),
 
1
 
Smeeth et al. do not discuss alternative, time-
honored explanations for the occurrence of cardio-
vascular events within three days after acute infec-
tions. A reasonable explanation could be that fever
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and the accompanying tachycardia trigger such
events, not to mention the procoagulant effects an
acute infection can have. The hypoxemia that ac-
companies a respiratory (but not urinary) infection
can adversely affect vulnerable tissue, not to men-
tion have procoagulant effects.
 
2
 
 A less common
phenomenon is a myocardial infarction masquer-
ading as a respiratory infection. In one recent study,
more than 40 percent of cases of myocardial infarc-
tion in women had the appearance of a respiratory
infection.
 
3
 
 The widely held view about the role that
inflammation plays in atherosclerosis and cardio-
vascular events has prevented recognition and dis-
cussion of the apparent paradox that common anti-
inflammatory agents, such as corticosteroids and
nonsteroidal antiinflammatory drugs (with the ex-
ception of aspirin), may actually increase, rather
than decrease, adverse cardiovascular outcomes.
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to the editor: 
 
Smeeth et al. found that persons
with acute infections have an increased risk of car-
diovascular and cerebrovascular events, whereas
those who have been vaccinated do not. They con-
clude that this “lends strong support to the concept
that systemic inflammation itself alters the proba-
bility of the occurrence of a vascular event.” We
believe that this conclusion based on their data is
flawed. Not discussed is the influence of acute in-
fection on stress and on demand-induced ischemia.
Acute infections, particularly those of the respira-
tory tract, may be associated with hemodynamic
stresses that are not typically induced by vaccina-
tion. These hemodynamic stresses in high-risk old-
er persons, such as those in the study by Smeeth et
al., who had an increased prevalence of coronary
artery disease, may account for the increased rates
of myocardial events noted in the study. Although
evidence for a link between inflammation and vascu-
lar events is abundant, demand-induced ischemia
due to acute hemodynamic stressors of a clinically
significant degree may be a more straightforward
explanation of the findings of this study.
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the authors reply: 
 
Dr. Bursztyn raises the ques-
tion of whether there might have been cases of mis-
diagnosis of myocardial infarction as respiratory
infection. We did consider this important point.
Our study identified an increase in the risk of myo-
cardial infarction or stroke after a case of urinary
tract infection or respiratory infection. We think it
unlikely that myocardial infection was misdiag-
nosed as urinary tract infection or that either uri-
nary tract infection or respiratory tract infection was
misdiagnosed as stroke. Therefore, our conclusions
that two different infectious processes increase the
rate of cardiovascular events seem secure. As for the
interesting question about associations between
antiinflammatory drugs and event rates, it is unfor-
tunate that the interpretation of the data are diffi-
cult because of confounding and the diversity of
underlying disease states. Although we recognize
that some drugs have detrimental effects, we are
less certain than Dr. Bursztyn that, as a group, drugs
that reduce inflammation are necessarily harmful in
terms of cardiovascular events.
In our article, we list several possible mecha-
nisms that might explain the association between
acute infection and a short-term increase in cardio-
vascular risk. Drs. Sharifi and Mofrad suggest an
additional one: that hemodynamic stresses may
have played a part in mediating the effect. We agree
with the correspondents that infection and systemic
inflammation increase the heart rate and can alter
hemodynamics and myocardial oxygen demand.
Although it is conceivable that these acute changes
may have contributed to the effect we observed, it
seems less likely that they would have persisted dur-
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ing the month or so in which we found an elevated
risk after infection. Furthermore, although this al-
ternative mechanism is plausible, we do not see how
this alters our conclusion that our finding “lends
strong support to the concept that systemic inflam-
mation itself alters the probability of the occurrence
of a vascular event.”
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Altered Nuclear Transfer
 
to the editor:  
 
Altered nuclear transfer is a proce-
dure that has been proposed as a morally accept-
able means of procuring human embryonic stem
cells.
 
1
 
 In their Perspective article, Melton et al. (Dec.
30 issue)
 
2
 
 appear to misunderstand, and therefore
prematurely dismiss, the promising possibilities of
this proposal.
The proposal for altered nuclear transfer, which
was developed in wide consultation with leading
scientists, moral philosophers, and religious au-
thorities, represents a “third option” — a techno-
logical solution to the current moral impasse re-
garding the destruction of human embryos to obtain
embryonic stem cells.
Using the techniques of somatic-cell nuclear
transfer, but with the intentional alteration of the
nucleus before transplantation, we could construct
a biologic entity that, from its very inception, lacked
the attributes and capacities of a human embryo.
Studies with mice already provide evidence that we
may be able to generate functional embryonic stem
cells from a system that is not an organism but is
biologically (and morally) more akin to tissue or
cell culture. There is a natural precedent for entities
that lack the characteristics of organisms, yet are
capable of generating embryonic stem cells or their
functional equivalent. Teratomas are germ-cell tu-
mors that generate all three primary embryonic
germ-layer cell types, as well as more advanced cells
and tissues. Yet these chaotic, disorganized, and
nonfunctional masses entirely lack the structural
and dynamic character of an organism.
Most of the objections raised by Melton et al. are
based on a mistaken identification of altered nucle-
ar transfer with silencing of the gene 
 
CDX2,
 
 but —
as was clearly stated in my presentation to the Pres-
ident’s Council on Bioethics — there are many po-
tential approaches involving the alteration of genes
that are necessary for early intercellular signaling,
cell differentiation, or integrated patterning of de-
velopment.
 
3
 
 The exact gene or combination of
genes will depend on the level of disorganization
deemed essential to fulfill the moral criteria of this
project.
Many Americans believe that a decent society
should not build the foundations of its biomedical
science on the intentional creation and destruction
of human embryos. Such a view is consistent with
the enduring traditions of our profession, encoded
in the Hippocratic oath and extended in the 1948
Declaration of Geneva, which explicitly states, “I will
maintain the utmost respect for human life, from
the time of conception.” Altered nuclear transfer is
not a “distraction” or a “diversion of resources” as
stated by Melton et al., but a morally reasonable and
technologically feasible proposal that honors the
important human goods being defended by both
sides of this difficult debate.
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the authors reply:  
 
We did not misunderstand
Hurlbut’s proposal. We focused on 
 
CDX2
 
 because
this is the example that Hurlbut offered, but our
point was more general. To repeat: “We see no basis
for concluding that the action of 
 
CDX2
 
 (or indeed
any other gene) represents a transition point at
which a human embryo acquires moral status.”
Hurlbut now acknowledges that “the exact gene
or combination of genes will depend on the level of
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